Facile biofunctionalization of silver nanoparticles for enhanced antibacterial properties, endotoxin removal, and biofilm control

International Journal of Nanomedicine

Volumn 10, Issue , 2015, Pages 2155-2171

  Lambadi, Paramesh Ramulu ^a   Sharma, Tarun Kumar ^a   Kumar, Piyush ^a   Vasnani, Priyanka ^a   Thalluri, Sitaramanjaneya Mouli ^a   Bisht, Neha ^a   Pathania, Ranjana ^a   Navani, Naveen Kumar ^a  

^a INDIAN INSTITUTE OF TECHNOLOGY ROORKEE   (India)

Author keywords

Biofilm inhibition; Biofunctionalization; Endotoxin removal; Nosocomial pathogen; Polymyxin B; Silver nanoparticles

Indexed keywords

CITRATE CAPPED NANOPARTICLE; ESCHERICHIA COLI ENDOTOXIN; NANOPARTICLE; POLYMYXIN B CAPPED SILVER NANOPARTICLE; SILVER NANOPARTICLE; STAINLESS STEEL; UNCLASSIFIED DRUG; ANTIINFECTIVE AGENT; ENDOTOXIN; METAL NANOPARTICLE; SILVER;

ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIAL GROWTH; BACTERICIDAL ACTIVITY; BIOFILM; CHEMICAL PROCEDURES; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG POTENCY; DRUG SYNTHESIS; ELECTROPLATING INDUSTRY; ENDOTOXIN REMOVAL; FLOW CYTOMETRY; FRACTIONAL INHIBITORY CONCENTRATION; GROWTH INHIBITION; INFECTION CONTROL; MATERIAL COATING; MEMBRANE DAMAGE; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; NONHUMAN; PHARMACOLOGICAL PARAMETERS; PSEUDOMONAS AERUGINOSA; SCANNING ELECTRON MICROSCOPY; STAINING; SURGICAL BLADE; SURGICAL EQUIPMENT; VIBRIO FLUVIALIS; CHEMISTRY; DRUG EFFECTS; ISOLATION AND PURIFICATION;

BACTERIA (MICROORGANISMS); PSEUDOMONAS AERUGINOSA; VIBRIO FLUVIALIS;

ANTI-BACTERIAL AGENTS; BIOFILMS; ENDOTOXINS; METAL NANOPARTICLES; SILVER;

EID: 84928138275     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S72923     Document Type: Article

References (46)

1. Magill SS, Edwards JR, Bamberg W, et al. Multistate point-prevalence survey of health care-associated infections. N Engl J Med. 2014;370:1198-1208.
2. Gristina AG. Implant failure and the immuno-incompetent fibro-inflammatory zone. Clin Orthop Relat Res. 1994;298:106-118.
3. Munford RS. Severe sepsis and septic shock: the role of gram-negative bacteremia. Annu Rev Pathol. 2006;1:467-496.
4. Hetrick EM, Schoenfisch MH. Reducing implant-related infections: active release strategies. Chem Soc Rev. 2006;35(9):780-789.
5. Guerrero G, Amalric J, Mutin PH, Sotto A, Lavigne JP. Inhibition of bacterial adhesion and prevention of biofilm formation: use of organic self-assembled monolayers on inorganic surfaces. Pathol Biol (Paris). 2009;57:36-43.
6. Defez C, Fabbro-Peray P, Cazaban M, Boudemaghe T, Sotto A, Daures JP. Additional direct medical costs of nosocomial infections: estimation from a cohort of patients in a French university hospital. J Hosp Infect. 2008;68:130-136.
7. Mei L, Lu Z, Zhang W, et al. Bioconjugated nanoparticles for attachment and penetration into pathogenic bacteria. Biomaterials. 2013;34(38):10328-10337.
8. Lara HH, Garza-Treviño EN, Ixtepan-Turrent L, Singh DK. Silver nanoparticles are broad-spectrum bactericidal and virucidal compounds. J Nanobiotechnol. 2011;9:30.
9. Veerapandian M, Yun K. Functionalization of biomolecules on nanoparticles: specialized for antibacterial applications. Appl Microbiol Biotechnol. 2011;90(5):1655-1667.
10. Ernest V, Gajalakshmi S, Mukherjee A, Chandrasekaran N. Enhanced activity of lysozyme-AgNP conjugate with synergic antibacterial effect without damaging the catalytic site of lysozyme. Artif Cells Nanomed Biotechnol. 2014;42(5):336-343.
11. Brown AN, Smith K, Samuels TA, Lu J, Obare SO, Scott ME. Nanoparticles functionalized with ampicillin destroy multiple-antibiotic-resistant isolates of Pseudomonas aeruginosa and Enterobacter aerogenes and methicillin-resistant Staphylococcus aureus. Appl Environ Microbiol. 2012;78(8):2768-2774.
12. Liu LH, Xu KJ, Wang HY, et al. Self assembled cationic peptide nanoparticles as an efficient antimicrobial agent. Nat Nanotechnol. 2009;4:457-463.
13. Wang H, Xu K, Liu L, et al. The efficacy of self assembled cationic antimicrobial peptide nanoparticles against Cryptococcus neoformans for the treatment of meningitis. Biomaterials. 2010;31:2874-2881.
14. Hancock RE, Sahl HG. Antimicrobial and host-defense peptides as new anti-infective therapeutic strategies. Nat Biotechnol. 2006;24:1551-1557.
15. Petty JT, Zheng J, Hud NV, Dickson RM. DNA-templated Ag nanocluster formation. J Am Chem Soc. 2004;126:5207-5212.
16. Jones MR, Osberg KD, Macfarlane RJ, Langille MR, Mirkin CA. Templated techniques for the synthesis and assembly of plasmonic nanostructures. Chem Rev. 2011;111:3736-3827.
17. Morrison DC, Jacobs DM. Binding of polymyxin B to the lipid A portion of bacterial lipopolysaccharides. Immunochemistry. 1976;13:813-818.
18. Sergeev BM, Kiryukhin MV, Rubtsova MY, Prusov AN. Synthesis of protein A conjugates with silver nanoparticles. Coll J. 2003;65:636-638.
19. Soonhyang P, Hicham C, Jody W, Nadeau JL. Antimicrobial activity and cellular toxicity of nanoparticle-polymyxin B conjugates. Nanotechnology. 2011;22:185101.
20. Munro CH, Smith WE, Garner M, Clarkson J, White PC. Characterization of the surface of a citrate-reduced colloid optimized for use as a substrate for surface-enhanced resonance Raman-scattering. Langmuir. 1995;11:3712-3720.
21. Clinical and Laboratory Standards Institute. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically, Approved Standard. 8th ed, M07-A8. Wayne, PA: CLSI; 2009.
22. Ghosh IN, Patil SD, Sharma TK, Srivastava SK, Pathania R, Navani NK. Synergistic action of cinnamaldehyde with silver nanoparticles against spore-forming bacteria: a case for judicious use of silver nanoparticles for antibacterial applications. Int J Nanomedicine. 2013;8:4721-4731.
23. Ruden S, Hilpert K, Berditsch M, Wadhwani P, Ulrich AS. Synergistic interaction between silver nanoparticles and membrane permeabilizing antimicrobial peptides. Antimicrob Agents Chemo. 2009;53:3538-3540.
24. Bendaoud M, Vinogradov E, Balashova NV, Kadouri DE, Kachlany SC, Kaplan JB. Broad-spectrum biofilm inhibition by Kingella kingae exopolysaccharide. J Bacteriol. 2011;15:3879-3886.
25. Inbakandan D, Kumar C, Abraham LS, Kirubagaran R, Venkatesan R, Khan SA. Silver nanoparticles with anti microfouling effect: a study against marine biofilm forming bacteria. Colloids Surf B Biointerfaces. 2013;111:636-643.
26. O'Toole GA. Microtiter dish biofilm formation assay. J Vis Exp. 2011;47:e2437.
27. O'Toole GA, Pratt LA, Watnick PI, Newman DK, Weaver VB, Kolter R. Genetic approaches to study of biofilms. Methods Enzymol. 1999;31:91-109.
28. Barraud N, Buson A, Jarolimek W, Rice SA. Mannitol enhances antibiotic sensitivity of persister bacteria in P. aeruginosa biofilms. PLoS One. 2013;8(12):e84220.
29. Stoodley HL, Costerton JW, Stoodley P. Bacterial biofilms: from the natural environment to infectious diseases. Nat Rev Microbiol. 2004;2:95-108.
30. Radzig MA, Nadtochenko VA, Koksharova OA, Kiwi J, Lipasova VA, Khmel IA. Antibacterial effects of silver nanoparticles on gram-negative bacteria: influence on the growth and biofilms formation, mechanisms of action. Colloids Surf B Biointerfaces. 2013;102:300-306.
31. Eby DM, Luckarift HR, Johnson GR. Hybrid antimicrobial enzyme and silver nanoparticle coatings for medical instruments. Appl Mater Interfaces. 2009;1:1553-1560.
32. Mock JJ, Barbic M, Smith DR, Schultz DA, Schultz S. Shape effects in plasmon resonance of individual colloidal silver nanoparticles. J Chem Phys. 2002;116:6755-6759.
33. Dhawan A, Sharma V. Toxicity assessment of nanomaterials: methods and challenges. Anal Bioanal Chem. 2010;398:589-605.
34. Socrates G. Infrared and Raman Characteristic Group Frequencies, Tables and Charts. Chichester, UK: John Wiley and Sons Ltd; 2001:3.
35. Formaggio F, Crisma M, Rossi P. The first water-soluble 310-helical peptides. Chem Eur J. 2000;6:4498-4504.
36. Toniolo C, Polese A, Formaggio F, Kamphuis CM. Circular dichroism spectrum of a peptide 310-helix. J Am Chem Soc. 1996;18:2744-2745.
37. Pathania R, Zlitni S, Barker C. Chemical genomics in Escherichia coli identifies an inhibitor of bacterial lipoprotein targeting. Nat Chem Biol. 2009;11:849-856.
38. Daugelavicius R, Bakiene E, Bamford DH. Stages of polymyxin B interaction with the Escherichia coli cell envelope. Antimicrob Agents Chemother. 2000;44(11):2969-2978.
39. Bondarenko O, Ivask A, Kakinen A, Kurvet I, Kahru A. Particle-cell contact enhances antibacterial activity of silver nanoparticles. PLoS One. 2013;8:e64060.
40. Sauer K, Camper AK, Ehrlich GD, Costerton JW, Davies DG. Pseudomonas aeruginosa displays multiple phenotypes during development as a biofilm. J Bacteriol. 2002;184(4):1140-1154.
41. Palmer J, Flint S, Brooks J. Bacterial cell attachment, the beginning of a biofilm. J Ind Microbiol Biotechnol. 2007;34:577-588.
42. Michael B, Frederik H, Franziska B, Weilenmann HU, Egli T. Assessment and interpretation of bacterial viability by using the LIVE/DEAD BacLight Kit in combination with flow cytometry. Appl Environ Microbiol. 2007;73:3283-3290.
43. Gião MS, Wilks SA, Azevedo NF, Vieira MJ, Keevil CW. Validation of SYTO 9/propidium iodide uptake for rapid detection of viable but non-cultivable Legionella pneumophila. Microb Ecol. 2009;58:56-62.
44. Héquet A, Humblot V, Berjeaud JM, Pradier CM. Optimized grafting of antimicrobial peptides on stainless steel surface and biofilm resistance tests. Colloids Surf B Biointerfaces. 2011;84(2):301-309.
45. Vincent JL, Laterre PF, Cohen J, et al. A pilot-controlled study of a polymyxin B-immobilized hemoperfusion cartridge in patients with severe sepsis secondary to intra-abdominal infection. Shock. 2005;23(5):400-405.
46. Davies B, Cohen J. Endotoxin removal devices for the treatment of sepsis and septic shock. Lancet Infect Dis. 2011;11:65-71.